Kura Oncology

Summary
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

History

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of solid tumors, lymphoma and blood cancers. Kura was established in 2013 with the vision of developing novel, targeted therapies that will have a meaningful impact on the lives of patients in need. Our portfolio includes both small molecule and antibody therapies and includes pioneering molecularly targeted oncology programs targeting ALK, PI3K and SETD2.


Mission
It is our mission to discover, develop and deliver innovative, targeted therapies to change the lives of patients with cancer.

Vision
Our vision is to become a leader in the field of oncology by developing novel, targeted drugs for the treatment of cancer.

Key Team

Mr. Thomas Doyle (Principal Accounting Officer & Sr. VP of Fin. and Accounting)

Mr. Pete De Spain (Sr. VP of Investor Relations & Corp. Communications)

Ms. Kirsten Flowers (Chief Commercial Officer & Chief Corp. Strategy Officer)

Dr. Stephen Dale M.D. (Chief Medical Officer)

Dr. Roger Bakale Ph.D. (VP and Head of CMC, Clinical & Commercial Manufacturing)

Mr. James E. Basta J.D., Esq. (Chief Compliance Officer & Corp. Sec.)

Ms. Teresa Brophy Bair Esq., J.D. (Chief Legal Officer & Corp. Sec.)


Recognition and Awards
Kura Oncology has been awarded many industry honors including 2020 OncLive's Giants of Cancer Care Top 10 Oncology Innovators, Medidata Excellence in Action Award, PharmaVoice 100 List, and OncLive's 2019 PMO Innovator Award.

References
Kura Oncology
Leadership team

Dr. Troy Edward Wilson J.D., Ph.D. (Chairman, CEO, Pres & Principal Financial Officer)

Dr. Marc Grasso M.D. (Advisor)

Ms. Kathleen Ford (Chief Operating Officer)

Products/ Services
Biopharma, Biotechnology, Genetics, Health Care, Medical
Number of Employees
100 - 500
Headquarters
La Jolla, California, United States
Established
2014
Company Registration
SEC CIK number: 0001422143
Traded as
KURA
Social Media
Wed Feb 28 2024
About

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with
Logo

Copyright 2023 © businessabc powered by ztudium